347 results on '"Strom, B L"'
Search Results
52. Energy Reserves of Individual Southern Pine Beetles (Coleoptera: Scolytidae) as Determined by a Modified Phosphovanillin Spectrophotometry Method2
- Author
-
Kinn, D. N., primary, Perry, T. J., primary, Guinn, F. H., primary, Strom, B. L., primary, and Woodring, J., primary
- Published
- 1994
- Full Text
- View/download PDF
53. Attractant and Disruptant Semiochemicals for Dendroctonus jeffreyi (Coleoptera: Curculionidae: Scolytinae).
- Author
-
STROM, B. L., SMITH, S. L., and BROWNIE, C.
- Subjects
JEFFREY pine ,PINE ,TREES ,PHEROMONES ,DENDROCTONUS jeffreyi - Abstract
Jeffrey pine, Pinus jeffreyi Greville and Balfour, is a dominant yellow pine and important overstory component of forests growing on diverse sites from southwestern Oregon to Baja California to western Nevada. The Jeffrey pine beetle, Dendroctonus jeffreyi Hopkins (Coleoptera: Curculionidae: Scolytinae), is monophagous on Jeffrey pine and its primary insect pest. Despite the importance of P. jeffreyi, difficult terrain, environmental concerns, and lack of roads can constrain pest management activities. Semiochemicals are often easier to apply and more environmentally acceptable than other options, but they are lacking in this system. Attractants have been identified, but field bioassays have been limited because of infrequent or short duration outbreaks and a lack of beetles during nonoutbreak periods. Disruptant semiochemicals have not been assessed for D. jeffreyi during outbreak conditions; however, commercially available semiochemicals have been implicated as disruptants for this bark beetle. The objective of this study was to identify the most effective commercially available attractant and disruptant semiochemicals for D. jeffreyi. Our highest observed catch occurred with the blend of 5% 1-heptanol and 95% n-heptane. When this was used to challenge potential disruptant semiochemicals, the combination of S-(-)-verbenone and the green leaf volatile blend (cis-3-Hexenol and 1-Hexanol) reduced trap catch by ≈80%. However, frontalin was most effective, reducing the number of D. jeffreyi caught by >96%. Within each year of the study, the percentage female of D. jeffreyi caught with our attractant decreased from start to end of the experimental period. On average, our first collection in a year (mid-June to early July) was 59% female, whereas our last (mid-August) was 34%. Frontalin was equally or more effective against females (the pioneering sex) than males, providing optimism that semiochemieal disruption may be possible for protecting Jeffrey pines from D. jeffreyi. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
54. Nonsteroidal anti-inflammatory drugs and neutropenia
- Author
-
Strom, B. L., primary
- Published
- 1993
- Full Text
- View/download PDF
55. Descriptive epidemiology of agranulocytosis
- Author
-
Strom, B. L., primary
- Published
- 1992
- Full Text
- View/download PDF
56. Prescriber adherence to pharmacokinetic monitoring service recommendations for aminoglycoside dosing and the risk of acute kidney injury.
- Author
-
Hennessy, S., Leonard, C. E., Localio, A. R., Cohen, A., Yang, W., Cheung, L., Strom, B. L., Herlim, M., and Feldman, H. I.
- Published
- 2011
- Full Text
- View/download PDF
57. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures
- Author
-
Strom, B. L., primary
- Published
- 1991
- Full Text
- View/download PDF
58. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers.
- Author
-
Margolis, David J., Kantor, Jonathan, Santanna, Jill, Strom, Brian L., Berlin, Jesse A., Margolis, D J, Kantor, J, Santanna, J, Strom, B L, and Berlin, J A
- Subjects
FOOT ulcers ,DIABETES complications ,THERAPEUTICS - Abstract
Objective: The goal of this study was to specifically estimate the effectiveness of platelet releasate, a widely available treatment administered by a proprietary group of wound care centers (WCCs) for the treatment of diabetic neuropathic foot ulceration.Research Design and Methods: Treatment effectiveness was estimated in a retrospective cohort study controlling for treatment selection bias using logistic regression-derived propensity scores.Results: Platelet releasate was more effective than standard care. The relative risk for a wound to heal after treatment with platelet releasate compared with standard care at a WCC varied from 1.14 (95% CI 1.03-1.27) to 1.59 (1.49-1.70). The effect was greatest in those with the most severe wounds, i.e., large wounds that affect deeper anatomical structures.Conclusions: Within the limitations of the ability of propensity score analysis to control for selection bias, platelet releasate is more effective than standard therapy. This effect is more pronounced in more severe wounds. Unfortunately, severe wounds have not been evaluated in randomized clinical trials of new interventions. We encourage the inclusion of these patients in future trials. [ABSTRACT FROM AUTHOR]- Published
- 2001
- Full Text
- View/download PDF
59. Defining the clinically important difference in pain outcome measures.
- Author
-
Farrar, J T, Portenoy, R K, Berlin, J A, Kinman, J L, Strom, B L, Farrar, John T, Portenoy, Russell K, Berlin, Jesse A, Kinman, Judith L, and Strom, Brian L
- Published
- 2000
- Full Text
- View/download PDF
60. Treatment of osteoporosis: are physicians missing an opportunity?
- Author
-
Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA, Freedman, K B, Kaplan, F S, Bilker, W B, Strom, B L, and Lowe, R A
- Abstract
Background: Medical treatment of women with established osteoporosis may decrease the incidence of future fractures. Postmenopausal women who have sustained a distal radial fracture have decreased bone-mineral density and nearly twice the risk of a future hip fracture. The purpose of this study was to evaluate the adequacy of diagnosis and treatment of osteoporosis in postmenopausal women following an acute fracture of the distal part of the radius.Methods: A retrospective cohort study was performed with use of a claims database that includes more than three million patients, from thirty states, enrolled in multiple health plans. All women, fifty-five years of age or older, who sustained a distal radial fracture between July 1, 1994, and June 30, 1997, were identified in the database. Only patients with at least six months of continuous and complete medical and pharmaceutical health-care coverage from the date of the fracture were enrolled, to ensure that all health-care claims would be captured in the database. This cohort of patients was then evaluated to determine the proportion who had undergone either a diagnostic bone-density scan or treatment with any recommended medication for established osteoporosis (estrogen, a bisphosphonate, or calcitonin) within six months following the fracture.Results: A search of the database identified 1,162 women, fifty-five years of age or older, who had a distal radial fracture. Of these 1,162 patients, thirty-three (2.8 percent) underwent a bone-density scan and 266 (22.9 percent) were treated with at least one of the medications approved for treatment of established osteoporosis. Twenty women had both a bone-density scan and drug treatment. Therefore, only 279 (24.0 percent) of the 1,162 women who sustained a distal radial fracture underwent either diagnostic evaluation or treatment of osteoporosis. There was a significant decrease in the rate of treatment of osteoporosis with increasing patient age at the time of the fracture (p < 0.0001).Conclusions: Current physician practice may be inadequate for the diagnosis and treatment of osteoporosis in postmenopausal women who have sustained a distal radial fracture. [ABSTRACT FROM AUTHOR]- Published
- 2000
61. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease.
- Author
-
Coogan, Patricia, Rosenberg, Lynn, Louik, Carol, Zauber, Ann, Stolley, Paul, Strom, Brian, Shapiro, Samuel, Coogan, P F, Rosenberg, L, Louik, C, Zauber, A G, Stolley, P D, Strom, B L, and Shapiro, S
- Abstract
Background: We undertook the present analyses to determine whether family history of colorectal cancer in a parent or sibling modifies the inverse association of nonsteroidal anti-inflammatory drug (NSAID) use with colorectal cancer risk.Methods: We used data from two case-control studies of colorectal cancer. The hospital-based Case Control Surveillance Study included 1526 patients with primary colorectal cancer, 4192 cancer controls and 6036 noncancer controls. A population-based study conducted in Massachusetts enrolled 1201 incident cases of colorectal cancer and 1201 community controls. Data on NSAID use and risk factors for colorectal cancer were collected by interview.Results: In both studies there was a reduction in the odds ratios among subjects who used NSAIDs regularly continuing into the previous year, regardless of family history. In the Case Control Surveillance data, the odds ratio was 0.4 (95% CI 0.2-0.9) among subjects with a family history and 0.5 (95% CI 0.4-0.7) among subjects without a family history. The comparable odds ratios in the Massachusetts data were 0.5 (95% CI 0.3-0.9) and 0.7 (95% CI 0.6-0.9).Conclusions: These data indicate that regular continuing NSAID use is associated with a reduced risk of colorectal cancer among persons with a family history of the disease, as well as those without such a history. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
62. Screening for colorectal cancer and other GI cancers.
- Author
-
Scotiniotis, I, Lewis, J D, and Strom, B L
- Published
- 1999
- Full Text
- View/download PDF
63. An efficient design for verifying disease outcome status in large cohorts with rare exposures and low disease rates.
- Author
-
Bilker, Warren B., Berlin, Jesse A., Gail, Mitchell H., Strom, Brian L., Bilker, W B, Berlin, J A, Gail, M H, and Strom, B L
- Published
- 1999
- Full Text
- View/download PDF
64. Primary care physicians' decisions to perform flexible sigmoidoscopy.
- Author
-
Lewis, James D., Asch, David A., Ginsberg, Gregory G., Hoops, Timothy C., Kochman, Michael L., Bilker, Warren B., Strom, Brian L., Lewis, J D, Asch, D A, Ginsberg, G G, Hoops, T C, Kochman, M L, Bilker, W B, and Strom, B L
- Subjects
SIGMOIDOSCOPY ,COLONOSCOPY ,MEDICAL care ,RECTUM tumors ,TUMOR prevention ,COLON tumor prevention ,AGE distribution ,CLINICAL competence ,COMPARATIVE studies ,DECISION making ,FIBER optics ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL screening ,PRIMARY health care ,QUESTIONNAIRES ,RESEARCH ,RESEARCH funding ,SEX distribution ,EVALUATION research ,ACQUISITION of data - Abstract
Objective: This study was designed to identify factors that influence primary care physicians' willingness to perform flexible sigmoidoscopy.Measurements: Using a mailed questionnaire, we surveyed all 161 primary care physicians participating in a large health care system. We obtained information on training, current practice patterns, beliefs about screening for colorectal cancer, and the influence of various factors on their decision whether or not to perform flexible sigmoidoscopy in practice.Main Results: Of the 131 physicians included in the analysis, 68 (52%) reported training in flexible sigmoidoscopy, of whom 36 (53%) were currently performing flexible sigmoidoscopy in practice. Time required to perform flexible sigmoidoscopy, availability of adequately trained staff, and availability of flexible sigmoidoscopy services provided by other clinicians were identified most often as reasons not to perform the procedure in practice. Male physicians were more likely than female physicians to report either performing flexible sigmoidoscopy or desiring to train to perform flexible sigmoidoscopy (odds ratio 2.61; 95% confidence interval 1.10, 6.23). This observed difference appears to be mediated through different weighting of decision criteria by male and female physicians.Conclusions: Approximately half of these primary care physicians trained in flexible sigmoidoscopy chose not to perform this procedure in practice. Self-perceived inefficiency in performing office-based flexible sigmoidoscopy deterred many of these physicians from providing this service for their patients. [ABSTRACT FROM AUTHOR]- Published
- 1999
- Full Text
- View/download PDF
65. The diagnosis of renal cell cancer in relation to hypertension (United States).
- Author
-
Rosenberg, Lynn, Stephenson, Wendy, Rao, R., Palmer, Julie, Strom, Brian, Shapiro, Samuel, Rosenberg, L, Stephenson, W P, Rao, R S, Palmer, J R, Strom, B L, and Shapiro, S
- Abstract
Objectives: Renal cell cancer has been associated with hypertension or with drugs to treat it in several studies. We assessed whether the association is explained by more frequent detection of early renal cell cancer among persons being treated for hypertension.Methods: The data were collected in our Case-Control Surveillance Study, in which patients aged 20 to 69 years were interviewed in hospitals in Baltimore, Boston, New York, and Philadelphia during 1976-1996. We compared 134 incident cases of renal cell cancer who were being treated with drugs for hypertension to 193 untreated cases with respect to the route to diagnosis and the stage.Results: The relative risk estimate for having been diagnosed incidentally during a routine examination or workup for another condition, relative to having been diagnosed because of symptoms of renal cell cancer, was 1.3 (95 percent confidence interval, 0.7-2.5). The estimate for diagnosis at stage I or II relative to stage III or IV was 1.2 (0.7-2.1).Conclusion: In Case-Control Surveillance Study data, the relative risk estimate for renal cancer among users of various classes of antihypertensive drugs is 1.8 or 1.9. The present results suggest that this association can, at most, be explained only partially by the selective diagnosis of renal cell cancer among persons being treated for hypertension. [ABSTRACT FROM AUTHOR]- Published
- 1998
- Full Text
- View/download PDF
66. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids.
- Author
-
Carson, J L, Strom, B L, Schinnar, R, Duff, A, and Sim, E
- Abstract
Purpose: To determine the incidence of upper gastrointestinal bleeding in patients treated with corticosteroids.Patients and Methods: The incidence of upper gastrointestinal tract bleeding was assessed in a cohort of 19,880 patients from the Michigan Medicaid billing database with dermatitis and/or asthma treated with corticosteroids during 1980 to 1984. The frequency of upper gastrointestinal bleeding was assessed within 60 days after each corticosteroid prescription.Results: The incidence of upper gastrointestinal bleeding in patients without a past history of upper gastrointestinal bleeding who were exposed to corticosteroids was only 2.8 cases per 10,000 person-months. The rate of upper gastrointestinal bleeding was notably higher in patients receiving anticoagulants and those with a prior history of upper gastrointestinal bleeding (23.0 and 15.9 cases per 10,000 person-months, respectively).Conclusion: Because the incidence of upper gastrointestinal bleeding in ambulatory patients treated with corticosteroids is so low, prophylactic therapy should be restricted to high-risk patients, if it is to be used at all. [ABSTRACT FROM AUTHOR]- Published
- 1991
- Full Text
- View/download PDF
67. Calcium channel blockers and the risk of cancer.
- Author
-
Rosenberg, Lynn, Rao, R. Sowmya, Palmer, Julie R., Strom, Brian L., Stolley, Paul D., Zauber, Ann G., Warshauer, Ellen, Shapiro, Samuel, Rosenberg, L, Rao, R S, Palmer, J R, Strom, B L, Stolley, P D, Zauber, A G, Warshauer, M E, and Shapiro, S
- Subjects
CALCIUM antagonists ,CANCER risk factors ,CARCINOGENICITY ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,MULTIVARIATE analysis ,RESEARCH ,RESEARCH funding ,TUMORS ,LOGISTIC regression analysis ,EVALUATION research ,RELATIVE medical risk ,DISEASE incidence ,CASE-control method - Abstract
Context: Recent epidemiologic studies have raised the concern that calcium channel blocker use may increase the risk of cancer overall and of several specific cancers.Objective: To assess whether calcium channel blocker use increases the risk of cancer overall and of specific cancers.Design: Case-control drug surveillance study based on data collected from 1983 to 1996.Setting: Hospitals in Baltimore, Md, New York, NY, and Philadelphia, Pa.Patients: A total of 9513 patients aged 40 to 69 years with incident cancer of various sites and 6492 controls aged 40 to 69 years admitted for nonmalignant conditions.Main Outcome Measures: Incident cancer overall and 23 specific cancers.Results: Calcium channel blocker use was unrelated to the risk of cancer overall (relative risk [RR], 1.1; 95% confidence interval [CI], 0.9-1.3). Use was not significantly associated with increased risks of individual cancers, including those previously implicated, except cancer of the kidney (RR, 1.8; 95% CI, 1.1 -2.7). Recent use, use for 5 or more years, and use of individual calcium channel blocker drugs were also not associated with cancer incidence. Use of beta-blockers and angiotensin-converting enzyme inhibitors was generally unrelated to cancer overall or individual cancers, but both were associated with kidney cancer (RR, 1.8; 95% CI, 1.3-2.5; and RR, 1.9; 95% CI, 1.2-3.0, respectively).Conclusions: The present study suggests that the use of calcium channel blockers is unrelated to an increase in the overall risk of cancer or of individual cancers, except kidney cancer, which has been associated with hypertension or drugs to treat hypertension in previous studies. [ABSTRACT FROM AUTHOR]- Published
- 1998
- Full Text
- View/download PDF
68. Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study.
- Author
-
Strom BL, Abrutyn E, Berlin JA, Kinman JL, Feldman RS, Stolley PD, Levison ME, Korzeniowski OM, Kaye D, Strom, B L, Abrutyn, E, Berlin, J A, Kinman, J L, Feldman, R S, Stolley, P D, Levison, M E, Korzeniowski, O M, and Kaye, D
- Abstract
Background: Although antibiotic prophylaxis against infective endocarditis is recommended, the true risk factors for infective endocarditis are unclear.Objective: To quantitate the risk for endocarditis from dental treatment and cardiac abnormalities.Design: Population-based, case-control study.Setting: 54 hospitals in the Philadelphia area.Patients: Persons with community-acquired infective endocarditis not associated with intravenous drug use were compared with community residents, matched by age, sex, and neighborhood of residence.Measurements: Information on demographic characteristics, host risk factors, and dental treatment was obtained from structured telephone interviews, dental records, and medical records.Results: During the preceding 3 months, dental treatment was no more frequent among case-patients than controls (adjusted odds ratio, 0.8 [95% CI, 0.4 to 1.5]). Of 273 case-patients, 104 (38%) knew of previous cardiac lesions compared with 17 controls (6%) (adjusted odds ratio, 16.7 [CI, 7.4 to 37.4]). Case-patients more often had a history of mitral valve prolapse (adjusted odds ratio, 19.4 [CI, 6.4 to 58.4]), congenital heart disease (adjusted odds ratio, 6.7 [CI, 2.3 to 19.4]), cardiac valvular surgery (adjusted odds ratio, 74.6 [CI, 12.5 to 447]), rheumatic fever (adjusted odds ratio, 13.4 [CI, 4.5 to 39.5]), and heart murmur without other known cardiac abnormalities (adjusted odds ratio, 4.2 [CI, 2.0 to 8.9]). Among case-patients with known cardiac lesions--the target of prophylaxis--dental therapy was significantly (P = 0.03) less common than among controls (adjusted odds ratio, 0.2 [CI, 0.04 to 0.7] over 3 months). Few participants received prophylactic antibiotics.Conclusions: Dental treatment does not seem to be a risk factor for infective endocarditis, even in patients with valvular abnormalities, but cardiac valvular abnormalities are strong risk factors. Few cases of infective endocarditis would be preventable with antibiotic prophylaxis, even with 100% effectiveness assumed. Current policies for prophylaxis should be reconsidered. [ABSTRACT FROM AUTHOR]- Published
- 1998
- Full Text
- View/download PDF
69. Mental health of the mothers of malnourished children.
- Author
-
DE MIRANDA, CLAUDIO TORRES, TURECKI, GUSTAVO, MARI, JAIR DE JESUS, ANDREOLI, SÉRGIO BAXTER, MARCOLIM, MARCO ANTONIO, GOIHMAN, SAMUEL, PUCCINI, ROSANA, STROM, BRIAN L, BERLIN, JESSE A, de Miranda, C T, Turecki, G, Mari, J de J, Andreoli, S B, Marcolim, M A, Goihman, S, Puccini, R, Strom, B L, and Berlin, J A
- Subjects
LOW birth weight ,COMPARATIVE studies ,MATERNAL & infant welfare ,RESEARCH methodology ,MEDICAL cooperation ,MENTAL health ,NUTRITION disorders ,QUESTIONNAIRES ,RESEARCH ,EVALUATION research ,DISEASE prevalence ,CASE-control method ,ODDS ratio - Abstract
Background: The objective of this study is to measure the association between protein-energy malnutrition (PEM) in children and their mothers' mental health, in a low income area in the city of Embú, São Paulo, Brazil.Methods: A case-control study was performed. Cases were 60 moderately and severely malnourished children (Gomez criteria) selected from two primary health care units. Controls consisted of 45 eutrophic children attending the same units. The main outcome measure was for the mothers to present a mental health score > 6 according with the 'Adult Psychiatric Morbidity Questionnaire' (QMPA), a psychiatric screening instrument.Results: Of mothers of children with PEM, 63% and 38% of mothers in the control group were QMPA positive: odds ratio (OR) = 2.8 (95% confidence interval [CI]: 1.2-6.9). Of PEM children, 27% had low birthweight (LBW = < 2500 g) and 6% of the control group had LBW. Interactions were found between: mothers' mental health and number of children (with > or = 4 children: OR = 20.0 [95% CI: 2.1-274.2], with < or = 3 children: OR = 1.6 [95% CI: 0.6-4.5), as well as mothers' mental health and maternal age (in women > 30: OR = 12.5 [95% CI: 2.0-93.4], in women < or = 30: OR = 1.5 [95% CI: 0.5-4.4].Conclusions: Mothers of children with PEM showed a higher rate of mental disturbances than mothers of eutrophic children. Unlike LBW, maternal age and number of children interact with mothers' mental health, increasing the association. Management of poor mental health may lead to mothers being better caretakers of their children and this may have a positive impact on PEM. [ABSTRACT FROM AUTHOR]- Published
- 1996
- Full Text
- View/download PDF
70. Using a claims database to investigate drug-induced Stevens-Johnson syndrome.
- Author
-
Strom, Brian L., Carson, Jeffrey L., Halpern, Allan C., Schinnar, Rita, Snyder, Ellen Sim, Stolley, Paul D., Shaw, Michele, Tilson, Hugh H., Joseph, Michael, Dai, Wanju S., Chen, Diane, Stern, Robert S., Bergman, Ulf, Lundin, Frank, Strom, B L, Carson, J L, Halpern, A C, Schinnar, R, Snyder, E S, and Stolley, P D
- Published
- 1991
- Full Text
- View/download PDF
71. The Promise of Pharmacoepidemiology.
- Author
-
Strom, B L
- Published
- 1987
- Full Text
- View/download PDF
72. Risk factors for gallbladder cancer. An international collaborative case-control study.
- Author
-
Strom, Brian L., Soloway, Roger D., Rios-Dalenz, Jaime L., Rodriguez-Martinez, Hector A., West, Suzanne L., Kinman, Judith L., Polansky, Marcia, Berlin, Jesse A., Strom, B L, Soloway, R D, Rios-Dalenz, J L, Rodriguez-Martinez, H A, West, S L, Kinman, J L, Polansky, M, and Berlin, J A
- Published
- 1995
- Full Text
- View/download PDF
73. Use of automated databases for pharmacoepidemiology research.
- Author
-
STROM, BRIAN L., CARSON, JEFFREY L., Strom, B L, and Carson, J L
- Published
- 1990
- Full Text
- View/download PDF
74. Epidemiology of sarcoidosis.
- Author
-
BRESNITZ, EDDY A., STROM, BRIAN L., Bresnitz, E A, and Strom, B L
- Published
- 1983
- Full Text
- View/download PDF
75. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia.
- Author
-
Gerson, Stanton L., Talbot, George H., Hurwitz, Shelley, Strom, Brian L., Lusk, Edward J., Cassileth, Peter A., Gerson, S L, Talbot, G H, Hurwitz, S, Strom, B L, Lusk, E J, and Cassileth, P A
- Subjects
PULMONARY aspergillosis ,ACUTE leukemia ,DISEASE risk factors ,CANCER chemotherapy ,LEUKEMIA complications ,AGRANULOCYTOSIS ,ANTINEOPLASTIC agents ,ASPERGILLOSIS ,BLOOD transfusion reaction ,COMPARATIVE studies ,EPIDEMIOLOGICAL research ,LEUKEMIA ,FUNGAL lung diseases ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,TIME ,EVALUATION research ,RELATIVE medical risk ,ACUTE diseases ,DISEASE complications - Abstract
A case-control study of patients with acute leukemia was done to identify significant risk factors for invasive pulmonary aspergillosis by reviewing the medical histories of 15 cases of pathologically proven invasive pulmonary aspergillosis and 45 controls. A history of lung or sinus disease, smoking, and multiple recurrences of leukemia did not increase the risk of invasive pulmonary aspergillosis. Cases and controls received similar chemotherapeutic regimens, and exposure to aminoglycosides, carbenicillin, trimethoprim-sulfamethoxazole, or corticosteroids was not significantly associated with development of invasive pulmonary aspergillosis. Among the factors tested, only granulocytopenia was associated with development of invasive pulmonary aspergillosis. Early in the course of granulocytopenia, patients developed signs of invasive pulmonary aspergillosis at a rate of approximately 1% per day. As the duration of granulocytopenia increased, the rate increased, approximating 4.3% per day between the 24th and 36th days. Of the 13 patients remaining granulocytopenic at 28 days, 7 had developed signs of invasive pulmonary aspergillosis. For patients with acute leukemia, granulocytopenia persisting longer than three weeks is the major risk factor for developing invasive pulmonary aspergillosis. [ABSTRACT FROM AUTHOR]
- Published
- 1984
- Full Text
- View/download PDF
76. Patient misunderstanding of dosing instructions.
- Author
-
Hanchak, Nicholas, Patel, Monica, Berlin, Jesse, Strom, Brian, Hanchak, N A, Patel, M B, Berlin, J A, and Strom, B L
- Subjects
DRUG therapy ,DRUG administration ,DRUG labeling ,LONGITUDINAL method ,MEDICAL prescriptions ,PATIENT compliance ,PATIENTS - Abstract
Objective: To compare outpatients' understanding of medication dosing instructions written in terms of daily frequency with patients' understanding of instructions specifying hourly intervals.Design: Prospective cohort study involving patient interviews.Setting: A university hospital outpatient pharmacy.Patients: Five hundred patients presenting new and refill prescriptions to the hospital outpatient pharmacy.Intervention: Patients were interviewed using a standardised questionnaire.Measurements and Main Results: Of the 71 patients with prescriptions specifying dosing instructions in hourly intervals (e.g., q6h), 55 (77%) misinterpreted the recommended frequency of dosage compared with only 4 (0.99%) of the 429 patients with dosing instructions specifying daily frequency (e.g., qid) (relative risk 83; 95% confidence interval 31-200). This difference remained when patient subgroups were evaluated by education level, new versus refill prescriptions, and analgesic versus nonanalgesic medications.Conclusions: This study indicates that the intended dosing regimen is frequently misunderstood when the physician writes outpatient prescriptions in hourly intervals. To promote optimal patient compliance, the outpatient prescription label should state the number of times a day a medication is to be taken. [ABSTRACT FROM AUTHOR]- Published
- 1996
- Full Text
- View/download PDF
77. Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis.
- Author
-
Hennessy, Sean, Strom, Brian, Berlin, Jesse, Brennan, Patrick, Hennessy, S, Strom, B L, Berlin, J A, and Brennan, P J
- Subjects
PNEUMOCYSTIS pneumonia ,HIV infection complications ,ANTI-infective agents ,COMPARATIVE studies ,DRUG allergy ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,URINARY tract infections ,EVALUATION research ,RETROSPECTIVE studies ,ANTIBIOTIC prophylaxis ,PREVENTION - Abstract
Objectives: To measure the incidence of cutaneous hypersensitivity reactions to cotrimoxazole in the setting of primary Pneumocystis carinii pneumonia (PCP) prophylaxis: to measure the incidence of severe reactions: and to identify predictors for these outcomes.Design: Retrospective cohort study.Setting: One university-based outpatient HIV clinic and one university-affiliated internal medicine and infectious disease medical practice.Patients: Two hundred thirty-six HIV-infected individuals receiving cotrimoxazole for primary PCP prophylaxis.Interventions: None.Main Outcome Measure: Occurrence of a cutaneous hypersensitivity reaction, defined as rash, fever, or pruritus that resulted in permanent discontinuation of cotrimoxazole. Severe reactions were defined as those resulting in hospital admission or systemic treatment with a corticosteroid. Cox regression was used to calculate relative rates (RRs) and 95% confidence intervals (CIs) for a number of clinical and laboratory variables.Measurements and Main Results: Forty-eight (20%) subjects developed cutaneous hypersensitivity reactions, with six (12.5%) of these being severe. In the unadjusted analysis, the following factors demonstrated at least borderline association: male gender [RR (95% CI) = 0.46 (0.21-0.99)], higher CD4 percentage [RR (95% CI) = 0.95 (0.90-1.00)], syphilis history [RR (95% CI) = 0.37 (0.13-1.04)], and higher total protein [RR (95% CI) = 0.70 (0.45-1.09)]. Adjustment for potential confounding by measured variables did not meaningfully change these results.Conclusions: Cutaneous hypersensitivity reactions to cotrimoxazole in the setting of primary PCP prophylaxis are common. Although male gender, higher CD4 percentage, syphilis history, and higher total protein have at least borderline associations with these reactions, routinely collected clinical and laboratory variables do not appear to be sufficiently associated with the reactions to permit development of a clinically useful prediction rule. [ABSTRACT FROM AUTHOR]- Published
- 1995
- Full Text
- View/download PDF
78. Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States).
- Author
-
Rosenberg, Lynn, Sowmya Rao, R., Palmer, Julie, Strom, Brian, Zauber, Ann, Warshauer, M., Stolley, Paul, Shapiro, Samuel, Rosenberg, L, Rao, R S, Palmer, J R, Strom, B L, Zauber, A, Warshauer, M E, Stolley, P D, and Shapiro, S
- Subjects
EPIDEMIOLOGY of cancer ,ACETAMINOPHEN ,CANCER ,COMPARATIVE studies ,KIDNEY tumors ,RESEARCH methodology ,MEDICAL cooperation ,REGRESSION analysis ,RENAL cell carcinoma ,RESEARCH ,URINARY organs ,EVALUATION research ,DISEASE incidence ,CASE-control method ,TRANSITIONAL cell carcinoma ,NONOPIOID analgesics - Abstract
Experimental and epidemiologic evidence have suggested that phenacetin use increases the risk of transitional cell cancers of the urinary tract. The drug is no longer marketed but a commonly used metabolite, acetaminophen, has been linked recently to an increased risk of renal cancer. We assessed the relation of acetaminophen use to the risk of transitional cell cancer of the urinary tract and of renal cell cancer with data from a hospital-based study of cancers and medication use conducted from 1976-96 in the eastern United States. We compared 498 cases of transitional cell cancer and 383 cases of renal cell cancer with 8,149 noncancer controls and 6,499 cancer controls and controlled confounding factors with logistic regression. For transitional cell cancer, the relative risk (RR) estimate for regular acetaminophen use that had begun at least a year before admission was 1.1 (95 percent confidence interval [CI] = 0.6-1.9) based on noncancer controls, and 0.9 (CI = 0.5-1.6) based on cancer controls. RR estimates for use that lasted at least five years, and for nonregular use, were also close to 1.0. For renal cell cancer, the corresponding estimates were again close to 1.0. Our results suggest that acetaminophen, as used in present study population, does not influence the risk of transitional cell cancer of the urinary tract or of renal cell cancer. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
79. Induced and spontaneous abortion in relation to risk of breast cancer (United States).
- Author
-
Palmer, Julie, Rosenberg, Lynn, Rao, R., Zauber, Ann, Strom, Brian, Warshauer, M., Stolley, Paul, Shapiro, Samuel, Palmer, J R, Rosenberg, L, Rao, R S, Zauber, A, Strom, B L, Warshauer, M E, Stolley, P D, and Shapiro, S
- Abstract
The relation of induced and spontaneous abortion to the risk of breast cancer is evaluated in a hospital-based case-control interview study conducted in three cities in the United States from 1985 through 1995. Cases were 1,803 women aged 25 to 64 years with newly diagnosed invasive breast cancer; controls were 4,182 women of the same ages admitted for conditions unrelated to reproductive factors. Other breast cancer risk-factors were controlled through multiple logistic regression. The reference for all analyses was women who had never had an abortion, either induced or spontaneous. Among parous women, the relative risk (RR) estimate was 1.1 (95 percent confidence interval [CI] = 0.9-1.5) for induced abortion overall, 1.0 (CI = 0.7-1.4) for abortion before the first birth, and 1.3 (CI = 1.0-1.8) for abortion after at least one birth. Among nulliparous women, the relative risk estimate for induced abortion was 1.3 (CI = 0.9-1.9). There was no trend of increased risk with number of abortions, nor was there consistent evidence of an increased risk in any particular subgroup. Spontaneous abortion was not associated with increased risk of breast cancer, either among nulliparous women or among parous women. These findings provide little support for the hypothesis that induced abortion increases breast cancer risk overall or in particular subgroups. [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
80. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis
- Author
-
Hennessy, S., Berlin, J. A., Kinman, J. L., Margolis, D. J., Marcus, S. M., and Strom, B. L.
- Published
- 2001
- Full Text
- View/download PDF
81. A comparison of sensitivity analyses of thc effect of wound duration on wound healing
- Author
-
Margolis, D. J., Berlin, J. A., and Strom, B. L.
- Published
- 1999
- Full Text
- View/download PDF
82. The relation of vasectomy to the risk of cancer.
- Author
-
Rosenberg, L, Palmer, J R, Zauber, A G, Warshauer, M E, Strom, B L, Harlap, S, and Shapiro, S
- Abstract
We previously reported a strong positive association between vasectomy and the risk of prostatic cancer that arose in multiple comparisons made within data collected from 1976 to 1988 in an ongoing hospital-based surveillance study of many exposures and diseases. We have reassessed this association with data collected in the surveillance study during 1988-1992 from a new set of patients (355 cases of prostatic cancer and 2,048 controls with nonmalignant conditions). Because some studies have reported increased relative risks of lung cancer and testicular cancer in vasectomized men, we also used the surveillance database (4,126 men with various cancers, 7,027 men with nonmalignant conditions) to assess the relation of vasectomy to the risk of these and other cancers. In the newly collected data, the multivariate relative risk estimate for prostatic cancer in vasectomized men was 1.2 (95% confidence interval (CI) 0.6-2.7). For lung cancer and testicular cancer, the relative risk estimates were 1.3 (95% CI 0.8-2.1) and 0.8 (95% CI 0.4-1.9), respectively; for lung cancer occurring > or = 15 years after vasectomy, the relative risk estimate was 1.9 but it was not statistically significant (95% CI 0.7-5.0). For pancreatic cancer, the relative risk estimate was 1.8 (95% CI 1.0-3.1). For each of the other cancers considered--malignant melanoma, large bowel cancer, bladder cancer, kidney cancer, lymphoma, leukemia, and other cancers--the relative risk estimate was 1.3 or less and compatible with a value of 1.0. The present data provide little support for an association of vasectomy with the risk of prostatic cancer or other cancers. In addition, the data from two sets of cases of prostatic cancer and controls interviewed consecutively illustrate that increased relative risks detected in screening for statistically significant associations may tend to have an upward bias and to be lower in subsequent data.
- Published
- 1994
- Full Text
- View/download PDF
83. Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus.
- Author
-
Strom, B L, Reidenberg, M M, West, S, Snyder, E S, Freundlich, B, and Stolley, P D
- Abstract
The authors undertook a case-control study to explore the many factors that have been postulated to be related to the etiology of systemic lupus erythematosus. A total of 195 cases of systemic lupus diagnosed in the Philadelphia, Pennsylvania, metropolitan area between 1985 and 1987 were compared with 143 controls, friends of the cases matched to them according to age (+/- 5 years) and sex. Through personal interviews and chart reviews, data were collected on demographic factors, personal and familial medical history, reproductive history, medication history, and environmental exposures. Associations were found between systemic lupus erythematosus and having a family history of autoimmune disease (age-, sex-, and race-adjusted odds ratio (OR) = 2.3, 95% confidence interval (CI) 1.2-4.6), a history of shingles (adjusted OR = 6.4, 95% CI 1.4-28.0), a history of hives (adjusted OR = 1.8, 95% CI 1.1-3.0), and a history of medication allergies (adjusted OR = 2.6, 95% CI 1.5-4.5). No association was present between systemic lupus erythematosus and either any use or recent use of oral contraceptives (e.g., OR = 0.6 (95% CI 0.2-1.4) for use in the 3 years prior to diagnosis), family history of multiple other diseases, or a history of numerous other infections or various other types of allergies. Thus, these data indicate that systemic lupus erythematosus is associated with a family history of autoimmune diseases, a history of shingles, and a history of allergies. In contrast, if the development of systemic lupus is affected by use of oral contraceptives, this effect must be extremely modest. These findings may help clarify the possible pathogenesis of systemic lupus erythematosus, and they provide clues as to when the presence of systemic lupus should be suspected.
- Published
- 1994
- Full Text
- View/download PDF
84. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer.
- Author
-
Rosenberg, L, Palmer, J R, Zauber, A G, Warshauer, M E, Lewis, J L, Strom, B L, Harlap, S, and Shapiro, S
- Abstract
The relation of oral contraceptive use to the risk of ovarian cancer was assessed with data collected during 1977-1991 from patients under 65 years of age in hospitals in Boston, New York, Philadelphia, and Baltimore. We compared 441 women with recently diagnosed invasive epithelial ovarian cancer to 2,065 control women. Logistic regression was used to control risk factors for ovarian cancer. The multivariate relative risk estimate decreased with the increasing duration of oral contraceptive use (p < 0.05): the estimate was close to 1.0 for duration categories of less than 3 years; it was reduced for the categories of 3-4 years of use and greater, but it did not decline further as the duration of use increased. For > or = 3 years of use, the estimate was 0.6 (95% confidence interval 0.4-0.8). The inverse association of risk with > or = 3 years of use was consistently present across categories of age, parity, interview year, and geographic area. It was apparent for as long as 15-19 years after cessation. Many different specific oral contraceptive formulations appeared related to a decreased risk; however, data were sparse for the newer types, particularly phasic preparations, and the ability to assess specific preparations in the context of use of multiple preparations was limited. The present data confirm previous reports of an inverse association of ovarian cancer risk with oral contraceptive use of several years in duration. They also suggest that the association may persist for as long as two decades and that it is not confined to any particular type of oral contraceptive formulation.
- Published
- 1994
- Full Text
- View/download PDF
85. Breast cancer in relation to the occurrence and time of induced and spontaneous abortion.
- Author
-
Rosenberg, L, Palmer, J R, Kaufman, D W, Strom, B L, Schottenfeld, D, and Shapiro, S
- Abstract
The authors evaluated whether an induced or spontaneous abortion during the first six months of gestation, particularly if it occurs before the first term pregnancy, increases the risk of breast cancer. Data from a case-control study of women under 70 years of age were used: 3,200 cases of breast cancer were compared with 4,844 controls with nonmalignant nongynecologic conditions. Among both nulliparous and parous women, the risk of breast cancer was not related to the number of induced or spontaneous abortions. After allowance for all identified potential confounding factors, the estimated relative risk for nulliparous women with an induced abortion relative to those who had never been pregnant was 1.3 (95% confidence interval (CI) 0.8-2.2), and for spontaneous abortion, the corresponding estimate was 0.9 (95% CI 0.5-1.5). Among parous women, the estimated relative risks were 1.2 (95% CI 0.9-1.6) for an induced abortion and 0.9 (95% CI 0.8-1.0) for a spontaneous abortion, relative to never having had an abortion of any type. The time of the abortion had little effect: The relative risk estimates were 0.9 (95% CI 0.5-1.4) for induced abortion before the first term birth, 1.4 (95% CI 1.0-1.9) for induced abortion first occurring after the first term birth, 0.9 (95% CI 0.7-1.2) for spontaneous abortion before the first term birth, and 0.9 (95% CI 0.7-1.0) for spontaneous abortion first occurring after the first term birth. Similar results were evident for women under age 40, among whom the frequency of induced abortion was relatively high. These data suggest that the risk of breast cancer is not materially affected by abortion, regardless of whether it occurs before or after the first term birth.
- Published
- 1988
- Full Text
- View/download PDF
86. Adult height and risk of breast cancer among US black women.
- Author
-
Palmer, J R, Rosenberg, L, Harlap, S, Strom, B L, Warshauer, M E, Zauber, A G, and Shapiro, S
- Abstract
Adult height has been positively associated with the risk of breast cancer in a number of recent investigations. The authors assessed height in relation to breast cancer risk in a case-control study of US black women aged 25-69 years; 674 hospital patients with newly diagnosed breast cancer and 1,155 controls hospitalized for nonmalignant conditions unrelated to height were interviewed. After control for multiple confounders, the relative risk estimate for women < 61 inches (< 154.9 cm) tall was 0.5 (95% confidence interval (Cl) 0.3-0.7) relative to the median height of 64-65 inches (162.6-165.1 cm). Among women > or = 61 inches (> or = 154.9 cm) tall, there was little indication of any variation in risk with increasing height. The findings suggest that short stature is associated with a decreased risk of breast cancer in US black women.
- Published
- 1995
- Full Text
- View/download PDF
87. Relation of benzodiazepine use to the risk of selected cancers: breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-Hodgkin's lymphoma, testis, Hodgkin's disease, thyroid, and liver.
- Author
-
Rosenberg, L, Palmer, J R, Zauber, A G, Warshauer, M E, Strom, B L, Harlap, S, and Shapiro, S
- Abstract
Some animal data have raised the possibility that benzodiazepines influence the risk of selected cancers. With data collected in 1977-1991 in a US hospital-based study, the authors assessed the relation of benzodiazepine use to the risk of 11 cancers: breast (6,056 patients), large bowel (2,203), malignant melanoma (1,457), lung (1,365), endometrium (812), ovary (767), non-Hodgkin's lymphoma (382), testis (314), Hodgkin's disease (299), thyroid (111), and liver (37). Cases were compared with cancer controls (3,777 patients with other cancers) and noncancer controls (1,919 patients admitted for acute nonmalignant disorders). Relative risks were estimated for benzodiazepine use at least 4 days a week for at least 1 month, initiated at least 2 years before admission (sustained use) by multiple logistic regression with control for confounding factors. Results derived with noncancer controls were similar to those derived with cancer controls. For sustained benzodiazepine use relative to no use, relative risk estimates for all 11 cancers were compatible with 1.0 at the 0.05 level of significance. Relative risk estimates for durations of at least 5 years were also compatible with 1.0, with the exceptions of an increased estimate, of borderline statistical significance, for endometrial cancer, and a decreased estimate for ovarian cancer. Relative risk estimates both for sustained use that continued into the 2-year period before admission and for sustained use that ended up to > or = 10 years previously were compatible with 1.0, suggesting a lack of tumor promotion and no increase in the risk after a latent interval. Results were also null for diazepam, chlordiazepoxide, and other benzodiazepines considered separately. The results suggest absence of association between benzodiazepine use and the cancers considered, with the evidence stronger for the cancers with larger numbers of subjects. The similarity of results derived with cancer and noncancer controls suggests that benzodiazepines do not influence the risk of cancer as a whole.
- Published
- 1995
- Full Text
- View/download PDF
88. Adverse Events after Protamine Administration in Patients Undergoing Cardiopulmonary Bypass: Risks and Predictors of Under-Reporting
- Author
-
Kimmel, S. E., Sekeres, M. A., Berlin, J. A., Goldberg, L. R., and Strom, B. L.
- Published
- 1998
- Full Text
- View/download PDF
89. Demographics, Health Behaviors, and Past Drug Use as Predictors of Recall Accuracy for Previous Prescription Medication Use
- Author
-
West, S. L., Savitz, D. A., Koch, G., Sheff, K. L., Strom, B. L., Guess, H. A., and Hartzema, A. G.
- Published
- 1997
- Full Text
- View/download PDF
90. Recall accuracy for prescription medications: self-report compared with database information.
- Author
-
West, S L, Savitz, D A, Koch, G, Strom, B L, Guess, H A, and Hartzema, A
- Abstract
A methodological study was performed in 1992 to evaluate the accuracy of self-reported use of nonsteroidal antiinflammatory drugs (NSAIDs) and noncontraceptive estrogens that had been dispensed during the previous 12 years. A sample of 560 individuals dispensed NSAIDs or estrogens, and 140 individuals without NSAID/estrogen dispensations were selected from the Group Health Cooperative pharmacy database. Demographic, behavioral, and drug information was ascertained by telephone interview for 356 persons with and 98 persons without NSAID/estrogen dispensations. Of those with only a single NSAID dispensation, 41% (95% confidence interval (CI) 32-50%) were able to recall any NSAID use compared with 85% (95% CI 76-94%) for those with multiple NSAID dispensations. Thirty percent (95% CI 24-36%) recalled the NSAID name, and 15% (95% CI 10-20%) recalled both the name and dose. For estrogens, 78% (95% CI 70-86%) recalled the name, but only 26% (95% CI 17-34%) recalled the name and dose. Age, but not sex, appeared to influence recall accuracy: Persons 50-65 years of age recalled the NSAID name more accurately than those aged 66-80 (odds ratio (OR) = 1.8, 95% confidence interval (CI) 1.0-3.4). A similar advantage was noted for 50- to 65-year-old women in recalling the estrogen name (OR = 1.5, 95% CI 0.6-3.9). Drug name was recalled more frequently for exposures stopped 2-3 years prior to interview than for those stopped 7-11 years prior (OR = 3.0, 95% CI 1.6-5.7, and OR = 2.4, 95% CI 0.9-6.7, for NSAIDs and estrogens, respectively). Specificity was consistently high, ranging from 92% to 100%. This study suggests significant underascertainment of self-reported prescription drug exposure but little evidence that exposures are overreported.
- Published
- 1995
- Full Text
- View/download PDF
91. Does gallbladder removal protect against subsequent myocardial infarction?
- Author
-
Strom, B L, Schinnar, R, Crown, V, Soloway, R, Stolley, P D, Rosenberg, L, Kaufman, D W, Helmrich, S P, and Shapiro, S
- Abstract
It has been suggested that gallbladder removal may protect against subsequent development of myocardial infarction because of increased gastrointestinal cholesterol excretion resulting from increased enterohepatic cycling. To test this hypothesis, the authors used data from two large case-control studies of myocardial infarction--one conducted in 1976-1979 in 155 US hospitals and one conducted in 1980-1983 in 78 US hospitals. First, 550 female myocardial infarction cases were compared to 1,658 controls. Simultaneously adjusting for possible confounding variables using logistic regression, the odds ratio for development of a myocardial infarction subsequent to cholecystectomy was 0.8 (95% confidence interval, 0.5-1.1). Second, 1,511 male myocardial infarction cases were compared to 3,837 controls. With similar adjustments, the odds ratio was 0.8 (95% confidence interval, 0.5-1.2). The risk did not decline as the interval following cholecystectomy increased. The present data are compatible with a protective effect of cholecystectomy on the risk of subsequent myocardial infarction, but they are not conclusive.
- Published
- 1986
- Full Text
- View/download PDF
92. Nonsedating antihistamines should be preferred over sedating antihistamines in patients who drive.
- Author
-
Hennessy, Sean, Strom, Brian L., Hennessy, S, and Strom, B L
- Subjects
PHYSIOLOGICAL effects of alcohol ,ANTIHISTAMINES ,FEXOFENADINE ,AUTOMOBILE driving ,PHYSIOLOGY ,COMPARATIVE studies ,ETHANOL ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,DIPHENHYDRAMINE ,TERFENADINE - Abstract
Editorial. Comments on a study conducted on the effects of alcohol, diphenhydramine and fexofenadine on driving. Data showing that the sedating antihistamine diphenhydramine impair psychomotor performance or measures of driving performance; Differences in the results of similar studies in experimental and nonexperimental settings.
- Published
- 2000
- Full Text
- View/download PDF
93. Oral contraceptives and vascular disease.
- Author
-
STOLLEY, PAUL D., STROM, BRIAN L., SARTWELL, PHILIP E., Stolley, P D, Strom, B L, and Sartwell, P E
- Abstract
This update on the cardiovascular risks of oral contraceptives unfortunately adds little to our original 1982 review for the following reasons: 1) There are many different formulations on the market, and they keep changing; 2) Women often use different formulations, stopping and starting as well as switching; 3) The statistical power of the studies often does not permit analyses by specific formulations; 4) The required information (brand name) is sometimes not collected or not collected reliably; 5) Apparently few case-control studies are being conducted to address these issues. Data that are available, interpreted cautiously, suggest either a continuance of the previously observed risk or a small to modest diminution with the use of the newer oral contraceptive formulations. The earlier advice to physicians still seems prudent and is briefly stated: 1) Try to avoid prescribing oral contraceptives for women over 35 years of age; 2) Women who smoke cigarettes should avoid using oral contraceptives, and users should not smoke; 3) Prescribe the formulation with the lowest dose and/or potency of estrogen that is effective and that does not cause unacceptable "breakthrough" bleeding; 4) Women with hypertension should be carefully monitored, and women who develop hypertension while on oral contraceptives should be switched to another form of contraception, if possible. Although oral contraceptives are the most effective form of contraception currently widely available, all risks of a contraceptive method must be compared with corresponding measures of effectiveness and with the risks of unwanted pregnancy. In particular, oral contraceptive users can reduce their risk of myocardial infarction by a reduction or elimination of cigarette smoking. [ABSTRACT FROM AUTHOR]
- Published
- 1989
- Full Text
- View/download PDF
94. Pharmacoepidemiology: current status, prospects, and problems.
- Author
-
Strom, Brian L., Tugwell, Peter, Strom, B L, and Tugwell, P
- Subjects
PHARMACOEPIDEMIOLOGY ,DRUG side effects ,PUBLIC health ,CLINICAL medicine - Abstract
Discusses issues surrounding pharmacoepidemiology. Discussion on adverse drug reactions; Factor which led to the development of the field of pharmacoepidemiology; Contributions of pharmacoepidemiology to public health; Impact of pharmacoepidemiology on clinical medicine.
- Published
- 1990
- Full Text
- View/download PDF
95. Prophylaxis of infective endocarditis. Revision of the march 1992 French consensus conference: French recommendations 2002 | Prophylaxie de l'endocardite infectieuse. Révision de la conférence de consensus de mars 1992: Recommandations 2002
- Author
-
Vildé, J. L., Chidiac, C., Byl, B., Choutet, P., Leport, C., Luciani, J., Perronne, C., Pothier, P., Quinet, B., Soussy, C. J., Stahl, J. P., Weinbreck, P., Dosquet, P., Etienne, J., Feki, A., Gibert, C., Michel, P. L., Danchin, N., Duval, X., Brochet, E., Andremont, A., Carlier, G., Christmann, D., Courillon-Mallet, A., Delahaye, F., Ducimetière, P., Mathieu, P., Pichelin, D., Ravery, V., Schabel, C., Sixou, M., Bouvet, A., Briançon, S., Chairay, J. P., Crémieux, A. C., Domart, Y., Habib, G., Hoen, B., Leroy, O., Moreillon, P., Ragot, J. P., Philippe Ravaud, Roche, Y., Strom, B. L., Thomas, D., Meer, J. T. M., Voiriot, P., Acar, C., Aliot, E., Artigou, J. Y., Auboyer, C., Aumaître, O., Aupetit, J. F., Avierinos, C., Bacq, Y., Bassand, J. P., Bastien, P., Becq-Giraudon, B., Bensaïd, J., Bertrand, M., Besnier, J. M., Beytout, J., Blanc, J. J., Bonnet, N., Bonhoure, J. P., Boy-Lefevre, M. L., Brochier, M., Broustet, J. P., Carlet, J., Caron, F., Chanoit, P., Chaptal, P. A., Chapuis, J., Charlemagne, D., Chauvel, C., Coste, P., Couetil, J. P., Daubert, J. C., Davy, C., Mello, G., Decazes, J. M., Delaye, J., Dersot, J. M., Derumeaux, G., Diebold, B., Djiane, P., Doco-Lecompte, T., Drahi, É, Ducardonnet, A., Dupont, B., Duran, D., Durand Gevigney, G., Dureuil, B., Fauchier, J. P., Gaillat, J., Gendrel, D., Grynberg, A., Guillemot, D., and Guize, L.
96. Design of a national distributed health data network
- Author
-
Maro, J. C., Platt, R., Holmes, J. H., Strom, B. L., Hennessy, S., ross lazarus, and Brown, J. S.
97. Developing a distributed research network to conduct population-based studies and safety surveillance
- Author
-
Holmes, J. H., Brown, J., Hennessy, S., Lane, K., Langer, R. D., ross lazarus, O Connor, P. J., Strom, B. L., and Platt, R.
98. Postmarketing studies of drug efficacy
- Author
-
Strom, B. L., primary
- Published
- 1985
- Full Text
- View/download PDF
99. Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis.
- Author
-
Gerson, S L, primary, Talbot, G H, additional, Lusk, E, additional, Hurwitz, S, additional, Strom, B L, additional, and Cassileth, P A, additional
- Published
- 1985
- Full Text
- View/download PDF
100. Frequency and Morbidity of Invasive Procedures
- Author
-
SCHROEDER, S. A., primary, MARTON, K. I., additional, and STROM, B. L., additional
- Published
- 1980
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.